Orforglipron: What the Evidence Actually Shows

This article exists to answer one question as precisely as a live database check allows, because the answer genuinely changes what everything else below means: as of this review, orforglipron is FDA-approved. It is marketed as FOUNDAYO — an oral tablet, not an injection — approved April 1, 2026, under NDA220934, confirmed independently through two separate live regulatory systems (openFDA's Drugs@FDA database and DailyMed's structured product label index) before any of the rest of this article was written. That approval is recent enough that a reader arriving here from an older article, a forum post, or a prior conversation may still reasonably believe orforglipron is an investigational drug in Phase 3 trials with no confirmed brand name. That was true until recently. It no longer is.

The live regulatory check — what it actually found

A direct openFDA Drugs@FDA query for "openfda.substance_name:ORFORGLIPRON", run live, returns exactly one application: NDA220934, sponsored by Eli Lilly and Company, with "openfda.brand_name" listed as FOUNDAYO. Its submission history shows exactly one entry — submission type ORIG (an original approval, not a supplement or amendment), submission status AP (approved), submission status date April 1, 2026, filed under submission class "Type 1 – New Molecular Entity"². A second, independent query by brand name alone ("openfda.brand_name:FOUNDAYO") returns the identical result — the same application number, the same approval date — confirming the brand-to-generic-name mapping rather than resting on a single lookup. DailyMed's own label index was checked the same way, twice: once searching "orforglipron," once searching "foundayo." Both searches return exactly one, identical result: "FOUNDAYO (ORFORGLIPRON) TABLET, FILM COATED [ELI LILLY AND COMPANY]," a live structured product label published April 3, 2026³. Two separate federal database systems, three separate query angles, one consistent answer: this is a real, dated, current FDA approval, not a rumor, a leaked filing, or a projection from a Phase 3 readout.

What Foundayo's actual label says

Foundayo's approved label is narrower than a reader might expect from "Eli Lilly's new GLP-1 pill." Its Indications and Usage section states it is indicated, in combination with a reduced-calorie diet and increased physical activity, "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition"⁴. That is a weight-management indication only — the label contains no separate type-2-diabetes glycemic-control indication at all, which is a genuinely different starting point than every other real GLP-1 drug in this corpus. Liraglutide, semaglutide, and dulaglutide all launched with a diabetes indication first and picked up a dedicated weight-management brand or supplement later; Foundayo has arrived the opposite way, approved for weight management with no diabetes indication (yet) on file.

Dosing is oral, once daily, with or without food, and the label is specific about handling: "Swallow tablets whole. Do not break, crush, or chew"⁴. The titration schedule starts low and climbs slowly — a starting dose of 0.8mg once daily, increased to 2.5mg after at least 30 days, then to 5.5mg after 30 more days, with further increases to 9mg, 14.5mg, or 17.2mg permitted after at least 30 days at each step, "based on treatment response and tolerability." The maximum approved dose is 17.2mg once daily⁴.

A genuinely different boxed warning story — read precisely

Every other GLP-1 drug this site covers carries a boxed warning about thyroid C-cell tumors observed in lifetime rodent studies, with FDA stating plainly it doesn't know whether that finding applies to humans. Foundayo's own label carries the same class-wide boxed warning — but for a specific, checkable reason that's worth reading in the label's own words rather than assuming it transfers automatically: "Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined⁴." In plain terms: unlike liraglutide, semaglutide, or dulaglutide, orforglipron's own nonclinical rodent studies did not reproduce the tumor finding, because the drug simply doesn't activate the rodent version of the GLP-1 receptor the way it activates the human one. FDA still applies the class-wide precautionary boxed warning and contraindication (personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2) — a conservative, class-based decision the label states honestly rather than dropping the warning just because this particular drug's own animal data came back negative. That's a precise, real distinction worth understanding exactly as stated, not rounded into either "orforglipron is safer" or "the warning doesn't matter here."

What kind of molecule this actually is

Foundayo's own mechanism-of-action text describes it plainly: "FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor... In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake⁴." What makes it structurally different from every injectable GLP-1 drug in this corpus is that it's a small molecule, not a peptide — dispensed as orforglipron calcium, a salt form suited to oral tablet manufacturing, confirmed directly from its own FDA product record (dosage form TABLET, route ORAL, six approved strengths)². That's the real basis for the once-daily pill format: unlike liraglutide, semaglutide, dulaglutide, and exenatide, which are all peptides requiring subcutaneous injection because they'd be broken down by digestion if swallowed, orforglipron is a small enough, chemically distinct enough molecule to survive oral dosing.

One dosing detail worth flagging precisely, because it's an easy trap for anyone comparing trial coverage to the approved label side by side: the pivotal Phase 3 trial tested orforglipron at 6mg, 12mg, and 36mg once daily — not the 0.8mg-to-17.2mg range the approved label actually uses¹⁴. Those are two different numbering conventions from two different points in this drug's development, not the same scale read two different ways; this article reports each source's own numbers as that source reports them, rather than implying they're directly comparable.

The Phase 3 trial data behind the approval

The pivotal trial, ATTAIN-1, was a real, multinational, randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity but no diabetes, testing orforglipron 6mg, 12mg, or 36mg once daily against placebo over 72 weeks¹. Mean body-weight change from baseline: -7.5% at the 6mg dose, -8.4% at 12mg, and -11.2% at the 36mg dose, versus -2.1% with placebo — every comparison reaching P<0.001¹. At the highest tested dose, more than half of patients (54.6%) lost at least 10% of their body weight, more than a third (36.0%) lost at least 15%, and nearly one in five (18.4%) lost at least 20% — compared with 12.9%, 5.9%, and 2.8% respectively on placebo¹. The trial also reported real improvements in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol alongside the weight-loss result. Discontinuation due to adverse events ran higher on orforglipron than placebo (5.3-10.3% vs 2.7%), and the most common adverse events were gastrointestinal, mostly mild to moderate — the same tolerability pattern every drug in this class carries¹.

Why this site doesn't have an orforglipron calculator

This isn't a close call the way it was for liraglutide, where a real injectable product had to be checked against whether compounded vial-and-diluent versions exist. Foundayo is dispensed as a film-coated oral tablet — confirmed directly from its own FDA product record — not an injection at all. This site's reconstitution calculator exists to do vial-to-syringe dosing arithmetic for injectable peptides; an oral tablet has no reconstitution step to calculate, categorically, regardless of compounding-market activity. A direct check of "sells.ts" and "other-compounds.ts" also found zero mentions of orforglipron or Foundayo among this site's reviewed providers.

What this means if you're considering it

Orforglipron is a real, newly FDA-approved drug — not an investigational compound, and not a rumor. As of this review it is approved specifically for weight management in adults with obesity, or overweight plus at least one weight-related comorbid condition, with a real Phase 3 trial behind it showing substantial, dose-dependent weight loss over 72 weeks. It carries the same class-wide thyroid boxed warning every GLP-1 drug in this corpus carries, even though its own nonclinical rodent data did not reproduce the underlying tumor finding — a precise nuance worth understanding rather than rounding into a safety claim either direction. It has no diabetes indication on file as of this review, and — because it's an oral small molecule rather than an injectable peptide — it sits entirely outside the compounded-injectable market this site's other calculator pages address. For how it fits alongside Eli Lilly's other real GLP-1 drugs, our dulaglutide evidence review and our tirzepatide vs. semaglutide evidence review cover the injectable side of that same company's GLP-1 portfolio.